After a challenging year for Sarepta Therapeutics, its chief executive has received his first equity grant in about eight ...

Sarepta Therapeutics ( ($SRPT) ) has issued an announcement. On December 10, 2025, Sarepta Therapeutics entered into exchange agreements to ...

Investing.com -- Sarepta Therapeutics (NASDAQ:SRPT) stock fell 8% on Thursday after the rare disease medicine specialist announced it would refinance approximately $291 million of its convertible ...

Wedbush has initiated Sarepta Therapeutics (SRPT) at outperform saying that a selloff that began earlier this year following ...

Investing.com -- Sarepta Therapeutics Inc (NASDAQ:SRPT) stock fell 3.7% on Thursday after the company announced a debt exchange agreement that will restructure a portion of its convertible notes.

Dyne Therapeutics plans to submit its next-gen Duchenne muscular dystrophy drug to the FDA after a successful trial.

Sarepta Therapeutics (NASDAQ:SRPT) leads in genetic therapies, contributing to ongoing discussions surrounding the nasdaq ...

When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The Massachusetts-based biotech company is under fire for refusing a request from the ...

The first milestone was hit in July, earning Arrowhead a $100 million payment. Sarepta made the payment by transferring $50 million in Arrowhead shares and paying the rest in cash, using proceeds from ...

On November 25, 2025, Sarepta Therapeutics filed two petitions for inter partes review (“IPR”) challenging Genzyme’s patents relating to ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy, challenger from Massachusetts biotech Dyne ...

SOMERSET, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, ...